The raw feed
Latest filings
Every transaction from every Form 4, as filed, newest first. Open-market buys (P) and sells (S) become signals; the rest is shown for completeness.
| Date | Company | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Coelho Rogerio Vivaldi director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $64.68 | $1.1M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Coelho Rogerio Vivaldi director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $40.29 | $504k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Coelho Rogerio Vivaldi director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,350 | $52.67 | $545k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Coelho Rogerio Vivaldi director | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,730 | $49.13 | $478k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Stephanie Okey director | DDisposition to issuer Common Stock | -6,400 | $85.00 | $544k | 5,925 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Stephanie Okey director | DDisposition to issuer Common Stock | -5,925 | $85.00 | $504k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Stephanie Okey director | DDisposition to issuer Stock Option (Right to Buy)derivative | -25,000 | $60.85 | $1.5M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Stephanie Okey director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $61.77 | $772k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Stephanie Okey director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $64.77 | $1.1M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Stephanie Okey director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $64.68 | $1.1M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Stephanie Okey director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $40.29 | $504k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Stephanie Okey director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,350 | $52.67 | $545k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Stephanie Okey director | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,730 | $49.13 | $478k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Weston Nichols director | DDisposition to issuer Common Stock | -16,300 | $85.00 | $1.4M | 5,925 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Weston Nichols director | DDisposition to issuer Common Stock | -5,925 | $85.00 | $504k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Weston Nichols director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $61.76 | $772k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Weston Nichols director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $61.77 | $772k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Weston Nichols director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $64.77 | $1.1M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Weston Nichols director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $66.71 | $1.2M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Weston Nichols director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $64.68 | $1.1M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Weston Nichols director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $40.29 | $504k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Weston Nichols director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,350 | $52.67 | $545k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Weston Nichols director | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,730 | $49.13 | $478k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Matthew K Fust director | DDisposition to issuer Common Stock | -22,836 | $85.00 | $1.9M | 5,925 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Matthew K Fust director | DDisposition to issuer Common Stock | -5,925 | $85.00 | $504k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Matthew K Fust director | DDisposition to issuer Stock Option (Right to Buy)derivative | -2,092 | $83.09 | $174k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Matthew K Fust director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $64.68 | $1.1M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Matthew K Fust director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $40.29 | $504k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Matthew K Fust director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,350 | $52.67 | $545k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Matthew K Fust director | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,730 | $49.13 | $478k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Caren Deardorf director | DDisposition to issuer Common Stock | -16,300 | $85.00 | $1.4M | 5,925 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Caren Deardorf director | DDisposition to issuer Common Stock | -5,925 | $85.00 | $504k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Caren Deardorf director | DDisposition to issuer Stock Option (Right to Buy)derivative | -35,000 | $65.70 | $2.3M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Caren Deardorf director | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,375 | $66.71 | $292k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Caren Deardorf director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $64.68 | $1.1M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Caren Deardorf director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $40.29 | $504k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Caren Deardorf director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,350 | $52.67 | $545k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Caren Deardorf director | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,730 | $49.13 | $478k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Camille L Bedrosian director | DDisposition to issuer Common Stock | -16,300 | $85.00 | $1.4M | 5,925 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Camille L Bedrosian director | DDisposition to issuer Common Stock | -5,925 | $85.00 | $504k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Camille L Bedrosian director | DDisposition to issuer Stock Option (Right to Buy)derivative | -25,000 | $68.92 | $1.7M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Camille L Bedrosian director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $64.77 | $1.1M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Camille L Bedrosian director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $66.71 | $1.2M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Camille L Bedrosian director | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | $64.68 | $1.1M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Camille L Bedrosian director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $40.29 | $504k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Camille L Bedrosian director | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,350 | $52.67 | $545k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Camille L Bedrosian director | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,730 | $49.13 | $478k | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Isabel Kalofonos Chief Commercial Officer | DDisposition to issuer Common Stock | -1,669 | $85.00 | $142k | 34,000 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Isabel Kalofonos Chief Commercial Officer | DDisposition to issuer Common Stock | -34,000 | $85.00 | $2.9M | 0 | 44 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Isabel Kalofonos Chief Commercial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -97,500 | $44.41 | $4.3M | 0 | 44 d ago |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.